ES2625632T3 - Método para la determinación rápida de la susceptibilidad o de la resistencia de las bacterias a los antibióticos - Google Patents
Método para la determinación rápida de la susceptibilidad o de la resistencia de las bacterias a los antibióticos Download PDFInfo
- Publication number
- ES2625632T3 ES2625632T3 ES13382271.8T ES13382271T ES2625632T3 ES 2625632 T3 ES2625632 T3 ES 2625632T3 ES 13382271 T ES13382271 T ES 13382271T ES 2625632 T3 ES2625632 T3 ES 2625632T3
- Authority
- ES
- Spain
- Prior art keywords
- antibiotic
- cell
- inhibits
- bacteria
- cell wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 81
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 69
- 229940088710 antibiotic agent Drugs 0.000 title description 50
- 230000003115 biocidal effect Effects 0.000 claims abstract description 107
- 210000004027 cell Anatomy 0.000 claims abstract description 78
- 230000001580 bacterial effect Effects 0.000 claims abstract description 66
- 230000004260 plant-type cell wall biogenesis Effects 0.000 claims abstract description 32
- 210000002421 cell wall Anatomy 0.000 claims abstract description 26
- 238000011534 incubation Methods 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 24
- 230000002596 correlated effect Effects 0.000 claims description 24
- 238000003786 synthesis reaction Methods 0.000 claims description 22
- 238000011156 evaluation Methods 0.000 claims description 14
- 230000012010 growth Effects 0.000 claims description 14
- 229930186147 Cephalosporin Natural products 0.000 claims description 9
- 229940124587 cephalosporin Drugs 0.000 claims description 9
- 150000001780 cephalosporins Chemical class 0.000 claims description 9
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 6
- 108010013639 Peptidoglycan Proteins 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 6
- 238000000386 microscopy Methods 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000010186 staining Methods 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 3
- 108010015899 Glycopeptides Proteins 0.000 claims description 3
- 102000002068 Glycopeptides Human genes 0.000 claims description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000339 bright-field microscopy Methods 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000001446 dark-field microscopy Methods 0.000 claims description 2
- 231100000673 dose–response relationship Toxicity 0.000 claims description 2
- 238000002135 phase contrast microscopy Methods 0.000 claims description 2
- 238000001907 polarising light microscopy Methods 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 description 29
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 24
- 229960000484 ceftazidime Drugs 0.000 description 24
- 238000012360 testing method Methods 0.000 description 20
- 241000588626 Acinetobacter baumannii Species 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 9
- 244000005700 microbiome Species 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003269 fluorescent indicator Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 3
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 3
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 3
- 229960002182 imipenem Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960002260 meropenem Drugs 0.000 description 3
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 238000002768 Kirby-Bauer method Methods 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- -1 ceftazidime Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229950011346 panipenem Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N 6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- CWXYHOHYCJXYFQ-UHFFFAOYSA-N Betamipron Chemical compound OC(=O)CCNC(=O)C1=CC=CC=C1 CWXYHOHYCJXYFQ-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000591286 Homo sapiens Myocardin-related transcription factor A Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102100034099 Myocardin-related transcription factor A Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950007599 betamipron Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229960000379 faropenem Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000002287 time-lapse microscopy Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382271.8A EP2821499B1 (en) | 2013-07-04 | 2013-07-04 | Method for the rapid determination of susceptibility or resistance of bacteria to antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2625632T3 true ES2625632T3 (es) | 2017-07-20 |
Family
ID=48906196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13382271.8T Active ES2625632T3 (es) | 2013-07-04 | 2013-07-04 | Método para la determinación rápida de la susceptibilidad o de la resistencia de las bacterias a los antibióticos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11319574B2 (https=) |
| EP (1) | EP2821499B1 (https=) |
| CN (1) | CN105358982B (https=) |
| AR (1) | AR096802A1 (https=) |
| BR (1) | BR112016000087B1 (https=) |
| CA (1) | CA2914708C (https=) |
| ES (1) | ES2625632T3 (https=) |
| NZ (1) | NZ630583A (https=) |
| WO (1) | WO2015003047A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3048174B1 (en) * | 2015-01-21 | 2018-11-07 | ABM Technologies, LLC | Procedure for the rapid determination of bacterial susceptibility to antibiotics that inhibit protein synthesis |
| EP3266877B1 (en) | 2016-07-08 | 2019-02-27 | Biomérieux | Flow cytometry data processing for antimicrobial agent sensibility prediction |
| EP3266878B1 (en) | 2016-07-08 | 2020-03-25 | bioMérieux | Flow cytometry data processing for antimicrobial agent sensibility prediction |
| WO2019023320A1 (en) | 2017-07-25 | 2019-01-31 | Arizona Board Of Regents On Behalf Of Arizona State University | FAST ANTIBIOTIC SENSITIVITY TESTING BY MONITORING THE SUBMICRON SCALE MOVEMENT OF SIMPLE BACTERIAL CELLS |
| CN107656056B (zh) * | 2017-08-29 | 2019-05-28 | 山东师范大学 | 一种基于细菌增长对细菌快速镜检的方法 |
| CN107421939A (zh) * | 2017-09-25 | 2017-12-01 | 江苏中新医药有限公司 | 一种快速定量检测抗菌药物敏感性的试剂及其应用方法 |
| DK3717659T3 (da) * | 2017-11-30 | 2022-10-17 | Ascilion Ab | Fremgangsmåde til at bestemme mikrobiel følsomhed over for antibiotiske midler |
| CN110760559B (zh) * | 2018-07-27 | 2023-11-17 | 张元珍 | 一种快速微生物抗生素敏感性检测方法 |
| WO2020072459A1 (en) * | 2018-10-02 | 2020-04-09 | Biofire Diagnostics, Llc | Bacterial response |
| CN112400023A (zh) * | 2019-03-14 | 2021-02-23 | 株式会社日立高新技术 | 药剂敏感性检查方法 |
| FR3103197B1 (fr) * | 2019-11-15 | 2024-08-30 | Biomerieux Sa | Determination par spectrometrie de masse de la sensibilite ou de la resistance de bacteries a un antibiotique |
| WO2021158700A1 (en) * | 2020-02-03 | 2021-08-12 | The Penn State Research Foundation | Systems and methods for antibacterial susceptibility testing using dynamic laser speckle imaging |
| CN112391441B (zh) * | 2021-01-13 | 2021-05-07 | 广州市胸科医院（广州市结核病防治所、广州市结核病治疗中心） | 一种基于荧光素的流式细胞术鉴定结核分枝杆菌利福平异质性耐药的方法 |
| CN112877396B (zh) * | 2021-01-18 | 2023-06-27 | 广东工业大学 | 一种评估抗性基因迁移风险的方法 |
| CN112877397B (zh) * | 2021-01-26 | 2022-04-22 | 北京大学 | 抗细胞内细菌感染的抗菌药物药效评估方法及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3327839A1 (de) | 1983-08-02 | 1985-02-14 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren und mittel zur empfindlichkeitspruefung von bakterien |
| DE69219989T2 (de) | 1991-05-06 | 1997-11-27 | Dade Microscan Inc | Schneller auswahltest für induzierbare beta-laktamase |
| IL101522A (en) | 1992-04-08 | 1997-09-30 | Combact Imaging Systems Ltd | Detection of microorganisms in a sample and determination of the sensitivity of microorganisms to antibiotics |
| BR9907161A (pt) | 1998-01-21 | 2000-10-24 | Secr Defence | Uso de um ensaio quanto à adenilato quinase em um teste in vitro, processos para determinar a suscetibilidade de uma bactéria a um reagente, para determinar a sensibilidade de uma bactéria a um antibiótico ou agente bioestático, para determinar a fase de cultivo de uma cultura bacteriana , e, kit de teste para analisar a sensibilidade de bactérias a antibióticos |
| RU2394911C2 (ru) * | 2005-05-11 | 2010-07-20 | Кр. Хансен А/С | Новые чувствительные к антибиотикам штаммы молочнокислых бактерий |
| ES2329637B1 (es) * | 2006-11-10 | 2010-09-22 | Universidad Autonoma De Madrid | Procedimiento para la determinacion de la fragmentacion del adn en microorganismos. |
| JP2013538567A (ja) * | 2010-08-12 | 2013-10-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗菌化合物を同定するおよび抗生物質感受性を決定する方法 |
| TWI532840B (zh) | 2011-07-05 | 2016-05-11 | 國立成功大學 | 微生物抗藥性與抗生素最小抑制濃度之檢測方法 |
| ES2396820B1 (es) | 2011-07-26 | 2014-01-31 | Universidad Autónoma de Madrid | Método para evaluar la integridad de la pared celular bacteriana. |
| KR101774995B1 (ko) | 2014-10-14 | 2017-09-05 | 주식회사 퀀타매트릭스 | 다양한 종류의 항생제 및 농도에서 반응하는 미생물 세포의 모양 및 성장 변화 분석을 이용한 신속한 항균제 감수성 검사 방법 및 이를 위한 자동화된 세포 이미지 분석 시스템 |
-
2013
- 2013-07-04 EP EP13382271.8A patent/EP2821499B1/en not_active Revoked
- 2013-07-04 ES ES13382271.8T patent/ES2625632T3/es active Active
-
2014
- 2014-07-02 WO PCT/US2014/045225 patent/WO2015003047A1/en not_active Ceased
- 2014-07-02 CN CN201480037680.2A patent/CN105358982B/zh active Active
- 2014-07-02 NZ NZ630583A patent/NZ630583A/en not_active IP Right Cessation
- 2014-07-02 US US14/322,626 patent/US11319574B2/en active Active
- 2014-07-02 CA CA2914708A patent/CA2914708C/en active Active
- 2014-07-02 BR BR112016000087-0A patent/BR112016000087B1/pt active IP Right Grant
- 2014-07-03 AR ARP140102482A patent/AR096802A1/es active IP Right Grant
-
2022
- 2022-04-25 US US17/728,442 patent/US12221646B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016000087B1 (pt) | 2022-04-05 |
| HK1206068A1 (en) | 2015-12-31 |
| US11319574B2 (en) | 2022-05-03 |
| US20150010940A1 (en) | 2015-01-08 |
| CA2914708A1 (en) | 2015-01-08 |
| CN105358982A (zh) | 2016-02-24 |
| NZ630583A (en) | 2017-09-29 |
| EP2821499A1 (en) | 2015-01-07 |
| EP2821499B1 (en) | 2017-02-15 |
| CN105358982B (zh) | 2018-09-18 |
| US12221646B2 (en) | 2025-02-11 |
| WO2015003047A1 (en) | 2015-01-08 |
| US20220243248A1 (en) | 2022-08-04 |
| AR096802A1 (es) | 2016-02-03 |
| BR112016000087A2 (https=) | 2017-07-25 |
| CA2914708C (en) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2625632T3 (es) | Método para la determinación rápida de la susceptibilidad o de la resistencia de las bacterias a los antibióticos | |
| AU2016224107B2 (en) | Bacteria identification and antimicrobial susceptibility test | |
| CN101790683B (zh) | 用于诊断微生物感染的组合物和装置 | |
| CN103717747A (zh) | 检测治疗剂抗性微生物的试剂盒和方法 | |
| Aydın et al. | Association of antibiotic resistance and biofilm formation in Escherichia coli ST131/O25b | |
| CN110760559A (zh) | 一种快速微生物抗生素敏感性检测方法 | |
| Kundu et al. | Comparative evaluation of phenotypic and genotypic methods for the rapid and cost-effective detection of carbapenemases in extensively drug resistant Klebsiella pneumoniae | |
| Haji Hashemi et al. | A study on prevalence of KPC producing from Klebsiella pneumoniae using Modified Hodge Test and CHROMagar in Iran | |
| Yi et al. | Unveiling the crucial role of ferroptosis in host resistance to streptococcus agalactiae infection | |
| Ahmed et al. | Determination of multidrug resistance and extended drug resistance pattern of pseudomonas aeruginosa in clinical isolates of tertiary care hospital Lahore | |
| Kırac et al. | Antimicrobial susceptibility pattern and multidrug resistance ındex in Pseudomonas aeruginosa among clinical isolates in Denizli, Turkey | |
| Al-Ghamdi et al. | Prevalence of Extensively and Pan-drug-resistant Acinetobacter spp | |
| RU2518249C1 (ru) | Способ определения неспецифической устойчивости патогенных микроогранизмов к антибиотикам на основании измерения каталитической активности фосфодиэстераз, расщепляющих циклический дигуанозинмонофосфат | |
| HK1206068B (en) | Method for the rapid determination of susceptibility or resistance of bacteria to antibiotics | |
| Muddassir et al. | An Analysis of High Frequency and Resistance Pattern in Pseudomonas Aeruginosa Isolated from Clinical Specimens Obtained from Tertiary Care Hospital | |
| Chiamaka et al. | Breast Cancer and Associated Bacterial Pathogens: Study of Breast Cancer Ulcers in Patients from National Hospital Cancer Center, Abuja, and their Antibiotic Sensitivity Profile | |
| Suneel et al. | Inducible clindamycin resistance in coagulase negative Staphylococci | |
| Eyo et al. | Carbapenemase-Producing Pseudomonas aeruginosa Isolates: Prevalence and Their Phenotypic Characteristics in Four Health Facilities in Calabar, Nigeria | |
| Sun et al. | Research Academy for Young Scientists | |
| Khan et al. | Prevalence of urinary tract infections and antibiotic effectiveness against uropathogens among females of different ages in Dera Ismail Khan, Khyber Pakhtunkhwa-Pakistan | |
| Kmiecikowski et al. | Description of Methodology for Testing the Synergistic and Additive Effects of Antibiotics in Vitro. | |
| EP3431988B1 (en) | Method to determine the state of the humoral immune system in a patient | |
| Özel et al. | An Innovative Method for Determining Amphotericin B Susceptibility in Leishmania infantum Isolates: A Modified Disk Elution Approach | |
| CA2977478C (en) | Bacteria identification and antimicrobial susceptibility test | |
| Alqurashi et al. | Microbes and Infectious Diseases |